Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251759 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL3671770 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL29607628 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL15251760 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL6055974 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL13084081 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL2069258 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL3803961 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL5620402 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL8885782 | 0.95 | DRD2 (0.46) | DRD2DRD1CYP19A1KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658276-B1 | TRANS-1(6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | LUNDBECK & CO AS H (DK) | 2012-10-10 | — | — | EP | disclosed |
| US-8227607-B2 | Processes for 4-((1R,35)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a salt thereof | H. LUNDBECK A/S (DK) | 2012-07-24 | — | — | US | disclosed |
| US-8076342-B2 | Malonate salt of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same | H. LUNDBECK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| US-20110053957-A1 | MALONATE SALT OF 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-03-03 | — | — | US | disclosed |
| US-20100324291-A1 | PROCESSES FOR 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE OR A SALT THEREOF | H. LUNDBECK A/S (DK) | 2010-12-23 | — | — | US | disclosed |
| US-7772240-B2 | used for the treatment of psychological disorders such as schizophrenia, anxiety, depression and bipolar disorder | H. LUNDBECK A/S (DK) | 2010-08-10 | — | — | US | disclosed |
| US-7767683-B2 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | H. LUNDBECK A/S (DK) | 2010-08-03 | — | — | US | disclosed |
| US-20060281759-A1 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| US-20060281758-A1 | used for the treatment of psychological disorders such as schizophrenia, anxiety, depression and bipolar disorder | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324291-A1 | PROCESSES FOR 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE OR A SALT THEREOF | CYP4Z1, HTR3C, HTR1D | DRD2 394/4885DRD1 321/4885CYP19A1 3725/4885 |
| US-20060281759-A1 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | HTR6, HTR1A, HTR2A | DRD2 70/4885DRD1 151/4885CYP19A1 3241/4885 |
| US-20110053957-A1 | MALONATE SALT OF 4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND USES OF SAME | MAL2, ME1, SYNJ1 | DRD2 462/4885DRD1 489/4885CYP19A1 4482/4885 |
| US-20060281758-A1 | used for the treatment of psychological disorders such as schizophrenia, anxiety, depression and bipolar disorder | DRD2, HTR2C, GABBR1 | DRD2 1/4885DRD1 36/4885CYP19A1 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.